title: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
abstract: OBJECTIVE
  To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  
  
  METHODS
  Therapy consisted of carmustine (40 mg/m(2)/d) on Days 1-3, oral etoposide (50 mg/d) on Days 1-21 and 29-49, and cisplatin (20 mg/m(2)/d i.v.) on Days 1-3 and 29-31. The regimen was repeated every 8 weeks for three cycles, with conventionally fractionated RT (5000 cGy with a 1000-cGy boost) delivered concurrently with the third cycle.
  
  
  RESULTS
  A total of 29 patients were enrolled between December 1999 and March 2001. For varying reasons (e.g., progression, refusal, death, or toxicity), only 48% completed the chemotherapy regimen and 76% completed RT. Grade 3-4 toxicities were observed in 14 patients (48%). The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial. To be considered an active treatment, a maximum of 9 patient deaths (of the first 25) were allowed before 700 days. However, 14 patients had died by 700 days after therapy.
  
  
  CONCLUSIONS
  Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.
authors.affiliation: Division of Medical Oncology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905 USA.
authors.forename: Ravi D
authors.initials: RD
authors.lastname: Rao
authors.forename: Sunil
authors.initials: S
authors.lastname: Krishnan
authors.forename: Tom R
authors.initials: TR
authors.lastname: Fitch
authors.forename: Paula J
authors.initials: PJ
authors.lastname: Schomberg
authors.forename: Robert P
authors.initials: RP
authors.lastname: Dinapoli
authors.forename: Kathleen
authors.initials: K
authors.lastname: Nordstrom
authors.forename: Bernd
authors.initials: B
authors.lastname: Scheithauer
authors.forename: Judith R
authors.initials: JR
authors.lastname: O'Fallon
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Maurer
authors.forename: Jan C
authors.initials: JC
authors.lastname: Buckner
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D005047:Etoposide; D002945:Cisplatin; D002330:Carmustine